MoneyWorks4Me

GlaxoSmithKline Pharmaceuticals informs about disclosure

25 Jun 2026 Evaluate
GlaxoSmithKline Pharmaceuticals has informed that the Company has received a Demand Notice dated 24th June 2026 from the National Pharmaceutical Pricing Authority. The relevant details to be disclosed are enclosed.

The above information is a part of company’s filings submitted to BSE.

Glaxosmithkline Phar Share Price

3031.95 51.90 (1.74%)
26-Aug-2026 15:11 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1910.20
Dr. Reddys Labs. 1189.15
Cipla 1412.75
Lupin 2195.80
Zydus Lifesciences 1147.15
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: